This is a preview of subscription content, log in via an institution to check access.
Data availability
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
References
Valenta P, Hadzijusufovica E, Hoermannd G, et al. Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. Leuk Res. 2017;59:47–54.
Lyon AR, López-Fernández T, Couch LS, et al. ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;2022(43):4229–61.
Motokawa T, Ikeda S, Ueno Y, et al. Comparison of dasatinib- and imatinib-related cardiotoxic adverse events in Japanese patients with chronic myeloid leukemia and gastrointestinal stromal tumor. Circ Rep. 2022;4:1–8.
Patras de Campaigno E, Bondon-Guitton E, Laurent G, et al. Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics. Br J Clin Parmacol. 2017;83:1544–55.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Dr. Kazuaki Tanabe has received lecture fees from Otsuka Pharmaceutical Co, Ltd. Drs. Yuka Kawanami, Kazuto Yamaguchi, Seita Yamasaki, Yuzo Kagawa, Hirotomo Sato, Nobuhide Watanabe, Akihiro Endo, Hiroyuki Yoshitomi declare that they have no conflict of interests.
Human rights statements and informed consent
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent was obtained from the patient for being included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Supplementary file1 (MP4 1610 KB)
Supplementary file2 (MPEG 4454 KB)
Supplementary file3 (MPEG 3280 KB)
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Kawanami, Y., Yamaguchi, K., Yamasaki, S. et al. Dasatinib-related left ventricular dysfunction in a patient with chronic myelogenous leukemia. J Echocardiogr (2023). https://doi.org/10.1007/s12574-023-00609-9
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12574-023-00609-9